Available Technologies
# of Displayed Technologies: 4 / 4
Categories
Intranasal Multivalent Vaccine Candidates for both SARS-CoV-2 and RSV
TS-005641 — This new composition of matter is a Intranasal multivalent vaccine candidates for both SARS-CoV-2 and RSV. This vaccine platform uses attenuated measles (MeV) and mumps (MuV) virus vectors to deliver optimized SARS‑CoV‑2 and RSV antigens. The intranasal multivalent vaccine was developed in response to the ongoing challenges posed by rapidly evolving COVID‑19 variants and the lack of effective RSV vaccines for infants and children.
- College:
- Inventors: Peeples, Mark; Thongpan, Ilada
- Licensing Officer: Zalucha, Ellen
Rapid Viral Inactivation by Gingipains
TS-004565 — A method for proteolytic inactivation of respiratory syncytial virus (RSV) with bacterial proteases purified from oral bacteria Porphyromonas gingivalis. Thus, a potential new antiviral for treatment of severe RSV infection.
Respiratory syncytial virus (RSV) is highly ocntagious and the second leading cause of lower respiratory tract infections in children, requiring hospitalization of about 3% of children under age 2 and with a mortality rate reported to be approximately 5x higher than influenza. RSV also poses signifi…
- College:
- Inventors: Bagaitkar, Juhi; Peeples, Mark; Rodriguez-Hernandez, Carlos
- Licensing Officer: Zalucha, Ellen
.png)
Increasing the Yield of Respiratory Syncytial Virus Live Attenuated Vaccines
TS-000214 — Preventing RSV attachment protein cleavage in vaccine producing cells to increase yield.
A widespread economic problem of RSV vaccine candidates is their inefficient production. RSV vaccine candidates are produced in Vero, a cell line isolated from African green monkey kidney. Infectious disease experts at Nationwide Children’s Hospital have discovered RSV grown in Vero cells has …
- College:
- Inventors: Peeples, Mark; Corry, Jacqueline; Kwilas, Steve
- Licensing Officer: Zalucha, Ellen
.png)
Enhanced Immunogenicity of a Modified Respiratory Syncytial Virus Vaccine with Mutations in One or Both Non-Structural Proteins
TS-000132 — Mutation of the RSV NS1/2 proteins to attenuate the virus and boost immunogenicity
Respiratory syncytial virus (RSV) is the leading cause of upper and lower respiratory tract infections in infants and young children, and the most common cause of bronchiolitis and pneumonia in children younger than 1-year of age. A vaccine does not exist in part because RSV non-structural protein g…
- College:
- Inventors: Peeples, Mark; Flano, Emilio; Mejias, Asuncion; Ramilo, Octavio; Teng, Michael Nan-hao (Mark)
- Licensing Officer: Zalucha, Ellen
